

16. A composition comprising the compound of Claim 1 and a vehicle.

17. Use of the compound of Claim 1 in the manufacture of a medicament for ~~A method of~~ treating and/or preventing migraine in a subject. ~~comprising administering to the subject in need thereof a therapeutically effective amount of the compound of Claim 1.~~

18. Use of the composition of Claim 16 in the manufacture of a medicament for ~~A method of~~ treating and/or preventing migraine in a subject. ~~comprising administering to the subject in need thereof a therapeutically effective amount of the composition of Claim 16.~~

19. Use of the compound of Claim 1 in the manufacture of a medicament for ~~A method of~~ agonizing the 5-HT_{1D} receptor in a subject. ~~comprising administering to the subject in need thereof a therapeutically effective amount of the compound of Claim 1.~~

20. Use of the compound of Claim 1 in the manufacture of a medicament for ~~A method of~~ agonizing the 5-HT_{1B} receptor in a subject. ~~comprising administering to the subject in need thereof a therapeutically effective amount of the compound of Claim 1.~~

21. Use of the compound of Claim 1 in the manufacture of a medicament for ~~A method of~~ selectively agonizing the 5-HT_{1D} receptor over the 5-HT_{1B} receptor in a subject. ~~comprising administering to the subject in need thereof a therapeutically effective amount of the compound of Claim 1.~~

22. The ~~method~~ use of Claim 21, wherein the compound of Claim 1 selectively agonizes the 5-HT_{1D} receptor over the 5-HT_{1B} receptor in a ratio of about 4:1.

23. The ~~method~~ use of Claim 21, wherein the compound of Claim 1 selectively agonizes the 5-HT_{1D} receptor over the 5-HT_{1B} receptor in a ratio of about 30:1.

24. Use of the compound of Claim 1 in the manufacture of a medicament for ~~A method of~~ providing functional antagonist activity at the 5-HT_{2B} receptor in a subject. ~~comprising administering to the subject in need thereof a therapeutically effective amount of the compound of Claim 1.~~

25. Use of the compound of Claim 1 in the manufacture of a medicament for ~~A method of~~ antagonizing the adrenergic alpha$_{2A}$ receptor in a subject. ~~comprising administering to the subject in need thereof a therapeutically effective amount of the compound of Claim 1.~~

26. Use of the compound of Claim 1 in the manufacture of a medicament for ~~A method of~~ antagonizing the adrenergic alpha$_{2B}$ receptor in a subject. ~~comprising administering to the subject in need thereof a therapeutically effective amount of the compound of Claim 1.~~

27. Use of the compound of Claim 1 in the manufacture of a medicament for~~A method of~~ antagonizing the adrenergic alpha$_{1A}$ receptor in a subject. ~~comprising administering to the subject in need thereof a therapeutically effective amount of the compound of Claim 1.~~

28. Use of the compound of Claim 1 in the manufacture of a medicament for ~~A method of~~ antagonizing the adrenergic alpha$_{1D}$ receptor in a subject. ~~comprising administering to the subject in need thereof a therapeutically effective amount of the compound of Claim 1.~~

29. Use of the compound of Claim 1 in the manufacture of a medicament for ~~A method of~~ antagonizing the adrenergic alpha$_{2C}$ receptor in a subject. ~~comprising administering to the subject in need thereof a therapeutically effective amount of the compound of Claim 1.~~

30. Use of the compound of Claim 1 in the manufacture of a medicament for ~~A method of~~ reducing agonism of the dopamine receptor in comparison to agonism of the dopamine receptor by dihydroergotamine in a subject. ~~comprising administering to the subject in need thereof a therapeutically effective amount of the compound of Claim 1.~~